Tysabri sales boost Elan Corp outlook

MOODY'S Investors Service has raised the outlook for Elan to positive from stable because of increasing sales of the Tysabri multiple sclerosis medicine.

Moody’s also confirmed the Dublin-based drugmaker’s B3 corporate family debt rating.

“The change in Elan’s rating outlook to positive reflects steady market acceptance of Tysabri approximately 18 months after the relaunch,” Moody’s senior vice-president Michael Levesque said.